The Center for Interventional Immunology collaborates with biotechnology and pharmaceutical partners to evaluate investigational therapies for type 1 diabetes (T1D). Through multicenter clinical trials, the team studies treatments designed to preserve insulin-producing beta cells, modulate immune responses, and improve long-term outcomes for people living with or at risk for T1D.
These studies evaluate therapies across multiple stages of disease, from delaying progression before diagnosis to preserving beta cell function after diagnosis. In addition to evaluating safety and efficacy, researchers investigate how therapies affect immune and metabolic pathways associated with T1D.
By working closely with industry partners, academic collaborators, and research participants, the Center for Interventional Immunology helps accelerate the development of new therapies and advance the goal of preventing, delaying, and ultimately improving treatment for T1D.
Additional Research Projects
Experimental Medicine Studies in Type 1 Diabetes
Dr. Speake leads BRI’s Experimental Medicine Unit, which seeks to understand how emerging therapies influence the immune and metabolic pathways involved in type 1 diabetes.
The Sound Life Project
The Sound Life Project studies healthy immune systems to better understand why individuals respond differently to infections, vaccinations, and other immune challenges.
Understanding Type 1 Diabetes Progression
The Speake Lab analyzes Type 1 Diabetes TrialNet data to better understand how type 1 diabetes develops and improve approaches to monitoring people at risk for the disease.
